Please assess the completion status of the following clinical trial:

Trial Title: Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of the Prostate~* Metastatic Disease with at least one lesion on bone scan and/or soft tissue on CT/MRI~* Demonstrated progression on abiraterone and/or enzalutamide~* Demonstrated PSA progression within 12 weeks of study participation~* Castrate testosterone levels at screening with continued Luteinizing hormone-releasing hormone (LHRH) therapy~* Eastern Cooperative Oncology Group (ECOG) score between 0-1~* Asymptomatic or mildly symptomatic~Exclusion Criteria:~* Candidates for cytotoxic chemotherapy~* Received more than one line of chemotherapy~* Received more than one treatment course of enzalutamide or abiraterone~* Inadequate washout of prohibited hormonally active agents or other prior treatments for prostate cancer (PCa)~* Known intra-cerebral disease or brain mets~* Spinal cord compression within 6 months~* Prior treatment with investigative androgen receptor (AR) agents

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EPI-506 (Type: EXPERIMENTAL): Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).